SeqLL Inc. (SQL)

Market Cap	5.70M
Revenue (ttm)	78,659
Net Income (ttm)	-4.09M
Shares Out	13.89M
EPS (ttm)	-0.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,732
Open	0.410
Previous Close	0.420
Day's Range	0.406 - 0.420
52-Week Range	0.230 - 2.400
Beta	n/a
Analysts	Buy
Price Target	3.06 (+628.57%)
Earnings Date	May 12, 2023

About SQL

SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. The company designs, develops, and manufactures genetic analysis technologies. It offers true single molecule sequencing (tSMS) platform, which offers a single molecule solution for DNA and RNA sequencing. The company has a collaboration agreement with Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. It serves academic and government ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Aug 27, 2021
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: SQL

Financial Performance

In 2022, SeqLL's revenue was $78,659, a decrease of -62.54% compared to the previous year's $209,995. Losses were -$4.09 million, 10.6% more than in 2021.

Analyst Forecast

According to 5 analysts, the average rating for SQL stock is "Buy." The 12-month stock price forecast is $3.06, which is an increase of 628.57% from the latest price.

Price Target

$3.06

(628.57% upside)

Analyst Consensus: Buy